{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:19:31Z","timestamp":1790403571752,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41375-018-0129-6","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T17:01:51Z","timestamp":1523984511000},"page":"1621-1630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia\u2014results of the AMLSG 11-08 trial"],"prefix":"10.1038","volume":"32","author":[{"given":"Peter","family":"Paschka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F","family":"Schlenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena I","family":"Gaidzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mridul","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Teleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3991-5721","authenticated-orcid":false,"given":"Markus","family":"Radsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Krauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-A.","family":"Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"K\u00fcndgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Heil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hertenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schw\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-8218","authenticated-orcid":false,"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ringhoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Girschikofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Heinicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"G\u00f6hring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"129_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"129_CR2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/asheducation-2013.1.209","volume":"2013","author":"P Paschka","year":"2013","unstructured":"Paschka P, D\u00f6hner K. Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? Hematol Am Soc Hematol Educ Program. 2013;2013:209\u201319.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"129_CR3","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1182\/blood.V91.9.3134","volume":"91","author":"T Okuda","year":"1998","unstructured":"Okuda T, Cai Z, Yang S, Lenny N, Lyu CJ, van Deursen JM, et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 1998;91:3134\u201343.","journal-title":"Blood"},{"key":"129_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/13776","volume":"23","author":"LH Castilla","year":"1999","unstructured":"Castilla LH, Garrett L, Adya N, Orlic D, Dutra A, Anderson S, et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet. 1999;23:144\u20136.","journal-title":"Nat Genet"},{"key":"129_CR5","doi-asserted-by":"publisher","first-page":"10398","DOI":"10.1073\/pnas.171321298","volume":"98","author":"Y Yuan","year":"2001","unstructured":"Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ, et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA. 2001;98:10398\u2013403.","journal-title":"Proc Natl Acad Sci USA"},{"key":"129_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1535-6108(02)00016-8","volume":"1","author":"M Higuchi","year":"2002","unstructured":"Higuchi M, O\u2019Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 2002;1:63\u201374.","journal-title":"Cancer Cell"},{"key":"129_CR7","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"129_CR8","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.2004.03.012","volume":"22","author":"RF Schlenk","year":"2004","unstructured":"Schlenk RF, Benner A, Krauter J, B\u00fcchner T, Sauerland C, Ehninger G, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22:3741\u201350.","journal-title":"J Clin Oncol"},{"key":"129_CR9","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/JCO.2005.15.610","volume":"23","author":"G Marcucci","year":"2005","unstructured":"Marcucci G, Mr\u00f3zek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:5705\u201317.","journal-title":"J Clin Oncol"},{"key":"129_CR10","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","volume":"364","author":"B L\u00f6wenberg","year":"2011","unstructured":"L\u00f6wenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364:1027\u201336.","journal-title":"N Engl J Med"},{"key":"129_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/onc.2010.494","volume":"30","author":"P Pittoni","year":"2011","unstructured":"Pittoni P, Piconese S, Tripodo C, Colombo MP. Tumorintrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene. 2011;30:757\u201369.","journal-title":"Oncogene"},{"key":"129_CR12","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMoa031046","volume":"350","author":"L Bullinger","year":"2004","unstructured":"Bullinger L, D\u00f6hner K, Bair E, Fr\u00f6hling S, Schlenk RF, Tibshirani R, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350:1605\u201316.","journal-title":"N Engl J Med"},{"key":"129_CR13","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1056\/NEJMoa040465","volume":"350","author":"PJ Valk","year":"2004","unstructured":"Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617\u201328.","journal-title":"N Engl J Med"},{"key":"129_CR14","doi-asserted-by":"publisher","first-page":"e0124241","DOI":"10.1371\/journal.pone.0124241","volume":"10","author":"X Gao","year":"2015","unstructured":"Gao X, Lin J, Gao L, Deng A, Lu X, Li Y, et al. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia. PLoS ONE. 2015;10:e0124241.","journal-title":"PLoS ONE"},{"key":"129_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1365-2141.2009.08035.x","volume":"148","author":"SC L\u00fcck","year":"2010","unstructured":"L\u00fcck SC, Russ AC, Du J, Gaidzik V, Schlenk RF, Pollack JR, et al. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. Br J Haematol. 2010;148:925\u201337.","journal-title":"Br J Haematol"},{"key":"129_CR16","unstructured":"Prescribing information for Sprycel. http:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf . Accessed 25 March 2017."},{"key":"129_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","volume":"66","author":"MM Schittenhelm","year":"2006","unstructured":"Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, et al. Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66:473\u201381.","journal-title":"Cancer Res"},{"key":"129_CR18","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1073\/pnas.1019625108","volume":"108","author":"Y Wang","year":"2011","unstructured":"Wang Y, Zhao L, Wu CF, Liu P, Shi L, Liang Y, et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA. 2011;108:2450\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"129_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood-2012-05-431486","volume":"121","author":"P Paschka","year":"2013","unstructured":"Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood. 2013;121:170\u20137.","journal-title":"Blood"},{"key":"129_CR20","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk RF, D\u00f6hner K, Krauter J, Fr\u00f6hling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909\u201318.","journal-title":"N Engl J Med"},{"key":"129_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2307\/2533377","volume":"50","author":"PF Thall","year":"1994","unstructured":"Thall PF, Simon R. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics. 1994;50:337\u201349.","journal-title":"Biometrics"},{"key":"129_CR22","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642\u20139.","journal-title":"J Clin Oncol"},{"key":"129_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"129_CR24","volume-title":"The statistical analysis of failure time data.","author":"JD Kalbfleisch","year":"1980","unstructured":"Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data.. New York: John Wiley & Sons, Inc; 1980."},{"key":"129_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141\u201354.","journal-title":"Ann Stat"},{"key":"129_CR26","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/sj.leu.2403009","volume":"17","author":"RF Schlenk","year":"2003","unstructured":"Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003;17:1521\u20138.","journal-title":"Leukemia"},{"key":"129_CR27","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/sj.leu.2403528","volume":"18","author":"RF Schlenk","year":"2004","unstructured":"Schlenk RF, Fr\u00f6hling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia. 2004;18:1798\u2013803.","journal-title":"Leukemia"},{"key":"129_CR28","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2010.28.6856","volume":"28","author":"RF Schlenk","year":"2010","unstructured":"Schlenk RF, D\u00f6hner K, Mack S, Stoppel M, Kir\u00e1ly F, G\u00f6tze K, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol. 2010;28:4642\u20138.","journal-title":"J Clin Oncol"},{"key":"129_CR29","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1182\/blood-2013-12-546283","volume":"123","author":"M Tassara","year":"2014","unstructured":"Tassara M, D\u00f6hner K, Brossart P, Held G, G\u00f6tze K, Horst HA, et al. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood. 2014;123:4027\u201336.","journal-title":"Blood"},{"key":"129_CR30","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation. N Engl J Med. 2017;377:454\u201364.","journal-title":"N Engl J Med"},{"key":"129_CR31","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00277-016-2810-z","volume":"95","author":"RF Schlenk","year":"2016","unstructured":"Schlenk RF, L\u00fcbbert M, Benner A, Lamparter A, Krauter J, Herr W, et al. All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 Study. Ann Hematol. 2016;95:1931\u201342.","journal-title":"Ann Hematol"},{"key":"129_CR32","doi-asserted-by":"publisher","first-page":"780","DOI":"10.3324\/haematol.2014.114884","volume":"100","author":"N Boissel","year":"2015","unstructured":"Boissel N, Renneville A, Leguay T, Lefebvre PC, Recher C, Lecerf T, et al. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica. 2015;100:780\u20135.","journal-title":"Haematologica"},{"key":"129_CR33","doi-asserted-by":"crossref","unstructured":"Marcucci G, Geyer S, Zhao J, Caroll AJ, Bucci D, Uy GL et al. Adding KIT inhibitor dasatinib (DAS) to chemotherapy overcomes the negative impact of KIT mutation\/over-expression in core binding factor (CBF) acute myeloid leukemia (AML): results from CALGB 10801 (Alliance). Blood. 2014;124:8.","DOI":"10.1182\/blood.V124.21.8.8"},{"key":"129_CR34","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"129_CR35","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/ng.3709","volume":"48","author":"ZJ Faber","year":"2016","unstructured":"Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016;48:1551\u20136.","journal-title":"Nat Genet"},{"key":"129_CR36","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","volume":"127","author":"N Duployez","year":"2016","unstructured":"Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127:2451\u20139.","journal-title":"Blood"},{"key":"129_CR37","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/leu.2013.186","volume":"27","author":"C Allen","year":"2013","unstructured":"Allen C, Hills RK, Lamb K, Evans C, Tinsley S, Sellar R, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia. 2013;27:1891\u2013901.","journal-title":"Leukemia"},{"key":"129_CR38","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1182\/blood-2012-11-466425","volume":"122","author":"C Santos Dos","year":"2013","unstructured":"Dos Santos C, McDonald T, Ho YW, Liu H, Lin A, Forman SJ, et al. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood. 2013;122:1900\u201313.","journal-title":"Blood"},{"key":"129_CR39","doi-asserted-by":"publisher","first-page":"e66915","DOI":"10.1371\/journal.pone.0066915","volume":"8","author":"Y Fang","year":"2013","unstructured":"Fang Y, Zhong L, Lin M, Zhou X, Jing H, Ying M, et al. MEK\/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia. PLoS ONE. 2013;8:e66915.","journal-title":"PLoS ONE"},{"key":"129_CR40","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bcp.2014.02.019","volume":"89","author":"N Xie","year":"2014","unstructured":"Xie N, Zhong L, Liu L, Fang Y, Qi X, Cao J, et al. Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells. Biochem Pharmacol. 2014;89:74\u201385.","journal-title":"Biochem Pharmacol"},{"key":"129_CR41","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/leu.2010.151","volume":"24","author":"N Chevalier","year":"2010","unstructured":"Chevalier N, Solari ML, Becker H, Pantic M, G\u00e4rtner F, Maul-Pavicic A, et al. Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib. Leukemia. 2010;24:1779\u201381.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0129-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0129-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0129-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:34:22Z","timestamp":1684618462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0129-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["129"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0129-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,17]]},"assertion":[{"value":"18 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Bristol Myers Squibb provided dasatinib as study drug and financial support to conduct the trial. The remaining authors declare that they have no onflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}